IN192160B - - Google Patents
Info
- Publication number
- IN192160B IN192160B IN651DE2000A IN192160B IN 192160 B IN192160 B IN 192160B IN 651DE2000 A IN651DE2000 A IN 651DE2000A IN 192160 B IN192160 B IN 192160B
- Authority
- IN
- India
- Prior art keywords
- loratadine
- particle size
- surface area
- dosage form
- oral dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN651DE2000 IN192160B (fr) | 2000-07-17 | 2000-07-17 | |
PT01940893T PT1303276E (pt) | 2000-07-17 | 2001-06-21 | Forma de dosagem biodisponivel de loratadina |
ES01940893T ES2230325T3 (es) | 2000-07-17 | 2001-06-21 | Doificacion oral bio-aprovechable de loratadine. |
DK01940893T DK1303276T3 (da) | 2000-07-17 | 2001-06-21 | Biotilgængelig doseringsform af loratadin |
PCT/IB2001/001098 WO2002005816A1 (fr) | 2000-07-17 | 2001-06-21 | Forme galenique biodisponible de l'oratadine |
BR0112597-4A BR0112597A (pt) | 2000-07-17 | 2001-06-21 | Forma biodisponìvel de dosagem de loratadina |
AT01940893T ATE278404T1 (de) | 2000-07-17 | 2001-06-21 | Bioverfügbare darreichungsform von loratadin |
DE60106266T DE60106266T2 (de) | 2000-07-17 | 2001-06-21 | Bioverfügbare darreichungsform von loratadin |
AU2001274381A AU2001274381A1 (en) | 2000-07-17 | 2001-06-21 | A bioavailable dosage form of loratadine |
EP01940893A EP1303276B1 (fr) | 2000-07-17 | 2001-06-21 | Forme galenique biodisponible de l'oratadine |
US09/888,268 US20020035119A1 (en) | 2000-07-17 | 2001-06-22 | Bioavailable dosage form of loratadine |
ZA200300439A ZA200300439B (en) | 2000-07-17 | 2003-01-16 | A bioavailable dosage form of loratadine. |
HK03107616A HK1055256A1 (en) | 2000-07-17 | 2003-10-21 | A bioavailable dosage form of loratadine. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN651DE2000 IN192160B (fr) | 2000-07-17 | 2000-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN192160B true IN192160B (fr) | 2004-02-28 |
Family
ID=11097068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN651DE2000 IN192160B (fr) | 2000-07-17 | 2000-07-17 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20020035119A1 (fr) |
EP (1) | EP1303276B1 (fr) |
AT (1) | ATE278404T1 (fr) |
AU (1) | AU2001274381A1 (fr) |
BR (1) | BR0112597A (fr) |
DE (1) | DE60106266T2 (fr) |
DK (1) | DK1303276T3 (fr) |
ES (1) | ES2230325T3 (fr) |
HK (1) | HK1055256A1 (fr) |
IN (1) | IN192160B (fr) |
PT (1) | PT1303276E (fr) |
WO (1) | WO2002005816A1 (fr) |
ZA (1) | ZA200300439B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1635847B1 (fr) | 2003-06-13 | 2019-07-31 | IDH Holding ApS | Traitement de symptomes associes a la vaginose bacterienne |
JP3881640B2 (ja) * | 2003-08-08 | 2007-02-14 | 塩野義製薬株式会社 | ロラタジンを含むドライシロップ剤 |
US20050069590A1 (en) * | 2003-09-30 | 2005-03-31 | Buehler Gail K. | Stable suspensions for medicinal dosages |
US20060160871A1 (en) * | 2004-12-07 | 2006-07-20 | Nektar Therapeutics | Stable non-crystalline formulation comprising losartan |
US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
CA2628716C (fr) * | 2005-11-10 | 2016-09-27 | Alphapharm Pty Ltd | Processus de regulation de la dimension de particule |
EP2114404A4 (fr) | 2006-12-21 | 2010-03-03 | Alphapharm Pty Ltd | Composé et composition pharmaceutiques |
EP2318350A4 (fr) * | 2008-07-25 | 2012-11-28 | Alphapharm Pty Ltd | ATOVAQUONE À DIAMÈTRE DE PARTICULES (D90) VARIANT DE PLUS DE 3 muM À ENVIRON 10 muM |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3980778A (en) * | 1973-10-25 | 1976-09-14 | The Upjohn Company | Anti-inflammatory steroid |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
IL131317A (en) * | 1999-08-09 | 2006-08-01 | Cts Chemical Ind Ltd | Binder for pharmaceutical compositions |
-
2000
- 2000-07-17 IN IN651DE2000 patent/IN192160B/en unknown
-
2001
- 2001-06-21 PT PT01940893T patent/PT1303276E/pt unknown
- 2001-06-21 AU AU2001274381A patent/AU2001274381A1/en not_active Abandoned
- 2001-06-21 DE DE60106266T patent/DE60106266T2/de not_active Expired - Fee Related
- 2001-06-21 BR BR0112597-4A patent/BR0112597A/pt not_active IP Right Cessation
- 2001-06-21 AT AT01940893T patent/ATE278404T1/de not_active IP Right Cessation
- 2001-06-21 WO PCT/IB2001/001098 patent/WO2002005816A1/fr not_active Application Discontinuation
- 2001-06-21 DK DK01940893T patent/DK1303276T3/da active
- 2001-06-21 EP EP01940893A patent/EP1303276B1/fr not_active Revoked
- 2001-06-21 ES ES01940893T patent/ES2230325T3/es not_active Expired - Lifetime
- 2001-06-22 US US09/888,268 patent/US20020035119A1/en not_active Abandoned
-
2003
- 2003-01-16 ZA ZA200300439A patent/ZA200300439B/en unknown
- 2003-10-21 HK HK03107616A patent/HK1055256A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1055256A1 (en) | 2004-01-02 |
DE60106266T2 (de) | 2006-02-23 |
ZA200300439B (en) | 2004-02-10 |
US20020035119A1 (en) | 2002-03-21 |
PT1303276E (pt) | 2005-02-28 |
BR0112597A (pt) | 2003-08-12 |
DE60106266D1 (de) | 2004-11-11 |
ATE278404T1 (de) | 2004-10-15 |
AU2001274381A1 (en) | 2002-01-30 |
DK1303276T3 (da) | 2005-02-07 |
EP1303276A1 (fr) | 2003-04-23 |
ES2230325T3 (es) | 2005-05-01 |
WO2002005816A1 (fr) | 2002-01-24 |
EP1303276B1 (fr) | 2004-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EG23943A (en) | Flash-melt oral dosage formulation | |
EP1365354A4 (fr) | Dispositif de comptage et d'acheminement de petits articles | |
HUP0203204A3 (en) | Oral dosage forms | |
EP1372392A4 (fr) | Forme posologique orale contenant de la nicotine | |
IL138471A0 (en) | Novel semiconductor materials and their uses | |
GB9929613D0 (en) | Manufacture of semiconductor material and devices using that material | |
IL154404A0 (en) | Oral solid dose vaccine | |
AU9272401A (en) | Cripto mutant and uses thereof | |
IL154012A0 (en) | Hydrogel-driven drug dosage form | |
CA2388671A1 (fr) | Aimant therapeutique buccal | |
HUP0500638A2 (en) | Flashmelt oral dosage formulation | |
IN192160B (fr) | ||
EP1164640A4 (fr) | Dispositif a semiconducteur et procede de fabrication correspondant | |
GB0025611D0 (en) | Tablet inserters | |
GB0130923D0 (en) | Semiconductor device manufacture and design | |
IL164154A0 (en) | Fine particle size pioglitazone | |
GB0023654D0 (en) | Device for administering doses of particulate material | |
HUP0301433A3 (en) | Use of antiprogestins for producung pharmaceutical compositions for induction of apoptosis in a cell | |
EP1357898A4 (fr) | Forme posologique orale a liberation regulee amelioree | |
EG22762A (en) | Receptacle and receptacle device | |
GB0030587D0 (en) | Oral administration of beneficial substances | |
HK1047232A1 (zh) | 口服劑型 | |
IL149461A0 (en) | Semiconductor nanocrystalline materials and their uses | |
GB9925069D0 (en) | Oral dosage form | |
PL341178A1 (en) | Oral pharmaceutical dosage forms |